Monoamine oxidases: to inhibit or not to inhibit.

R. R. Ramsay; M. B. Gravestock

doi:10.2174/1389557033405287

Monoamine oxidases: to inhibit or not to inhibit.

R. R. Ramsay^*, M. B. Gravestock

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed.

Original language	English
Pages (from-to)	129-136
Number of pages	8
Journal	Mini reviews in medicinal chemistry
Volume	3
Issue number	2
DOIs	https://doi.org/10.2174/1389557033405287
Publication status	Published - 1 Jan 2003

Access to Document

10.2174/1389557033405287

Cite this

@article{f4cc7d286207408d814a99c00635afe6,

title = "Monoamine oxidases: to inhibit or not to inhibit.",

abstract = "Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed.",

author = "Ramsay, \{R. R.\} and Gravestock, \{M. B.\}",

year = "2003",

month = jan,

day = "1",

doi = "10.2174/1389557033405287",

language = "English",

volume = "3",

pages = "129--136",

journal = "Mini reviews in medicinal chemistry",

issn = "1389-5575",

publisher = "Bentham Science Publishers",

number = "2",

}

TY - JOUR

T1 - Monoamine oxidases

T2 - to inhibit or not to inhibit.

AU - Ramsay, R. R.

AU - Gravestock, M. B.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed.

AB - Monoamine oxidase (MAO) inhibitors were developed as antidepressants but many drugs, including the novel oxazolidinone antibacterial agents, share similar molecular properties and have MAO inhibitory activity. Factors important for binding antidepressants and modifications to decrease binding of oxazolidinones to avoid undesirable vascular effects are discussed.

UR - https://www.scopus.com/pages/publications/0038624568

U2 - 10.2174/1389557033405287

DO - 10.2174/1389557033405287

M3 - Review article

C2 - 12570845

AN - SCOPUS:0038624568

SN - 1389-5575

VL - 3

SP - 129

EP - 136

JO - Mini reviews in medicinal chemistry

JF - Mini reviews in medicinal chemistry

IS - 2

ER -

Monoamine oxidases: to inhibit or not to inhibit.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this